Lymphoma Clinical Trials in New York

Showing 81-100 of 344 trials

MB-105 in Patients With CD5 Positive T-cell Lymphoma

NCT06534060

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.

Lymphoma, T-Cell

March Biosciences Inc46 participantsStarted Feb 2025

San Diego, California, United States • Denver, Colorado, United States • Tampa, Florida, United States +9 more locations

RECRUITINGPHASE2< 1 mile

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.

Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc244 participantsStarted Nov 2014

Tucson, Arizona, United States • San Francisco, California, United States • Santa Monica, California, United States +173 more locations

MB-105 in Patients With CD5 Positive T-cell Lymphoma

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma Trials in Other Cities

Photopheresis in Early-stage Mycosis Fungoides

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Other Conditions in New York